首页> 外文期刊>Pakistan journal of medical sciences. >Vaginal micronized progesterone capsule versus vaginal progesterone gel for lutheal support in normoresponder IVF/ICSI-ET cycles
【24h】

Vaginal micronized progesterone capsule versus vaginal progesterone gel for lutheal support in normoresponder IVF/ICSI-ET cycles

机译:阴道微粉黄体酮胶囊与阴道黄体酮凝胶在正常反应者IVF / ICSI-ET周期中支持黄体

获取原文
           

摘要

Objective: To compare the outcomes of luteal phase support by micronized progesteron vaginal capsule 600mg/day and progesterone vaginal gel 180mg/day in the normoresponder IVF/ICSI-ET cycles of the patients down-regulated via GnRH agonist long protocol or fixed antagonist protocol below 40 years of age.Methods: A total of 463 normoresponder cycles between January 2013 and December 2013 were retrospectively analyzed. Those with a BMI>28 kg/m2, any kind of uterine, ovarian or adnexial pathology, any significant systemic, endocrine or metabolic disease or who were reported as azoospermia, were excluded from the study. The patients were grouped according to the usage of micronized progesterone vaginal capsule 600mg/day (Group 1) or progesterone vaginal gel 180mg/day (Group 2) as luteal phase support. Treatment cycle characteristics and pregnancy outcomes were compared between groups.Results: Group-I included 220 cycles and group 2 included 243 cycles. Although the MII oocyte percentage among the total number of MII oocytes was significantly higher in Group-II (77.5% and 80.2%; p=0.034), positive ?-hCG (32.3% and 21.8%; p=0.015) and clinical pregnancy (27.3% and 17.7%; p=0.018) rates were significantly higher in Group-I. No difference was observed between groups regarding the ongoing pregnancy rates (23.2% and 17.3%; p=0.143).Conclusion: Micronized progesterone vaginal capsule 600mg daily used for luteal support in the IVF/ICSI-ET cycles was observed to significantly increase the biochemical and clinical pregnancy rates compared to progesterone vaginal gel 180mg daily. However, no difference was observed between two groups regarding ongoing pregnancy rates.?doi: http://dx.doi.org/10.12669/pjms.312.6613How to cite this:Sofuoglu K, Gun I, Sahin S, Ozden O, Tosun O, Eroglu M. Vaginal micronized progesterone capsule versus vaginal progesterone gel for lutheal support in normoresponder IVF/ICSI-ET cycles. Pak J Med Sci 2015;31(2):314-319. doi: http://dx.doi.org/10.12669/pjms.312.6613This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译:目的:比较以下经GnRH激动剂长期方案或固定拮抗剂方案下调的normoresponder IVF / ICSI-ET周期中,微粉化黄体酮阴道胶囊600mg /天和黄体酮阴道凝胶180mg /天黄体期支持的结果方法:回顾性分析2013年1月至2013年12月之间的463个正常反应周期。 BMI> 28 kg / m2,任何类型的子宫,卵巢或附件病理,任何严重的系统性,内分泌性或代谢性疾病或被报告为无精子症的患者均排除在研究范围之外。根据微粉化黄体酮阴道胶囊600mg /天(组1)或黄体酮阴道凝胶180mg /天(组2)作为黄体期支持剂对患者进行分组。比较各组的治疗周期特征和妊娠结局。结果:第一组包括220个周期,第二组包括243个周期。尽管II组的MII卵母细胞总数中的MII卵母细胞百分比显着更高(II组为77.5%和80.2%; p = 0.034),β-hCG阳性(32.3%和21.8%; p = 0.015)和临床妊娠(第一组的比率分别为27.3%和17.7%; p = 0.018)。两组之间的持续妊娠率没有差异(分别为23.2%和17.3%; p = 0.143)。结论:在IVF / ICSI-ET周期中,每天使用600mg黄体酮化的黄体酮阴道胶囊支持黄体功能显着增加了生化指标与临床妊娠率相比,孕激素阴道凝胶每天180mg。但是,两组之间的持续妊娠率没有差异。doi:http://dx.doi.org/10.12669/pjms.312.6613如何引用此信息:Sofuoglu K,Gun I,Sahin S,Ozden O,Tosun O,Eroglu M.阴道微粉化孕酮胶囊与阴道孕酮凝胶相比,在normoresponder IVF / ICSI-ET周期中可以作为路德支持。 Pak J Med Sci 2015; 31(2):314-319。 doi:http://dx.doi.org/10.12669/pjms.312.6613。这是根据知识共享署名许可(http://creativecommons.org/licenses/by/3.0)的条款分发的开放获取文章。允许在任何媒体中无限制地使用,分发和复制,但要正确引用原始作品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号